ORIC Pharmaceuticals (NASDAQ:ORIC) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORIC) in a report released on Thursday morning, Benzinga reports.

Several other equities research analysts have also recently weighed in on ORIC. JPMorgan Chase & Co. reduced their price objective on ORIC Pharmaceuticals from $19.00 to $18.00 and set an overweight rating on the stock in a research note on Wednesday, March 27th. HC Wainwright increased their price target on ORIC Pharmaceuticals from $15.00 to $21.00 and gave the company a buy rating in a report on Thursday, March 21st. Citigroup dropped their price objective on shares of ORIC Pharmaceuticals from $15.00 to $14.00 and set a buy rating for the company in a research note on Tuesday, May 7th. Finally, Wedbush increased their target price on shares of ORIC Pharmaceuticals from $12.00 to $20.00 and gave the company an outperform rating in a research note on Friday, March 1st. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of Buy and a consensus target price of $20.00.

ORIC Pharmaceuticals Stock Performance

NASDAQ ORIC opened at $7.01 on Thursday. The stock has a 50 day moving average price of $8.76 and a 200-day moving average price of $10.31. ORIC Pharmaceuticals has a one year low of $5.27 and a one year high of $16.65. The company has a market capitalization of $472.61 million, a P/E ratio of -3.89 and a beta of 1.18.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its quarterly earnings data on Monday, May 6th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.07. As a group, equities analysts predict that ORIC Pharmaceuticals will post -1.68 EPS for the current fiscal year.

Hedge Funds Weigh In On ORIC Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Virtu Financial LLC bought a new stake in shares of ORIC Pharmaceuticals during the first quarter worth $225,000. NEA Management Company LLC bought a new stake in ORIC Pharmaceuticals during the 1st quarter valued at about $20,625,000. Price T Rowe Associates Inc. MD grew its stake in ORIC Pharmaceuticals by 140.5% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,566,736 shares of the company’s stock worth $21,543,000 after acquiring an additional 915,175 shares in the last quarter. Vanguard Group Inc. grew its stake in ORIC Pharmaceuticals by 27.9% in the 1st quarter. Vanguard Group Inc. now owns 2,882,055 shares of the company’s stock worth $39,628,000 after acquiring an additional 629,536 shares in the last quarter. Finally, ProShare Advisors LLC purchased a new position in shares of ORIC Pharmaceuticals during the first quarter worth approximately $161,000. Hedge funds and other institutional investors own 95.05% of the company’s stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.